ICT is building a comprehensive platform of CAR-T products for blood cancers and solid tumors, including an allogeneic CAR-T development program. CAR-T therapies of the future will combine stem cells, gene editing and gene therapy, and ICT is making breakthroughs to combine these technologies, including advances in leveraging hematopoietic stem cells.
Chimeric Antigen Receptor T-cells (CAR-T) are created by coupling the antigen-binding site of a tumor-recognizing antibody and the intracellular signaling domain of a T-cell of a patient through gene transduction, so that the cell expresses CAR. After being recoded, the T-cells of the patient are able to generate a large quantity of tumor-specific CAR-T cells.
Blood and Liquid Cancer
ICTCAR003 – Leading the Field in China
ICT’s most advanced development programs are in blood and liquid cancer. ICTCAR003 is a CAR-T candidate targeting CD19 in development for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) and is ICT’s lead product in China. It is currently available to Chinese patients through investigator-sponsored trials, and an IND has been submitted to the CFDA.
ICTCAR014 – Armored dnPD1+CD19CAR Construct
Research has shown that the inhibition of PD1 may enhance CAR-T cell function. ICTCAR014 targets CD19 and PD1. ICTCAR014 is ICT’s armored dnPD1+CD19CAR construct and will be ICT’s lead candidate in the United States. ICT expects to submit an IND to the U.S. FDA in 1H19.
ICT is developing multiple next-generation CAR-T candidates to target TSHR for thyroid cancer (ICTCAR023) and MUC-1 for breast and pancreatic cancer (ICTCAR043, ICTCAR046). Proof of concept trials are underway in China.
Allogeneic CAR-T Platform
ICT is leveraging its expertise in stem cells, gene editing and gene therapy to develop an allogeneic CAR-T platform